Gene expression analysis of B‐lymphoma cells resistant and sensitive to bortezomib *

The proteasome inhibitor bortezomib has shown impressive clinical activity alone and in combination with conventional and other novel agents for the treatment of multiple myeloma (MM). Although bortezomib is known to be a selective proteasome inhibitor, the downstream mechanisms of cytotoxicity and drug resistance are poorly understood. However, resistance to bortezomib as a single agent develops in the majority of patients, and activity in other malignancies has been less impressive. To elucidate mechanisms of bortezomib resistance, we compared differential gene expression profiles of bortezomib‐resistant SUDHL‐4 and bortezomib‐sensitive SUDHL‐6 diffuse large B‐cell lymphoma lines in response to bortezomib. At concentrations that effectively inhibited proteasome activity, bortezomib induced apoptosis in SUDHL‐6 cells, but not in SUDHL‐4 cells. We showed that overexpression of activating transcription factor 3 (ATF3), ATF4, ATF5, c‐Jun, JunD and caspase‐3 is associated with sensitivity to bortezomib‐induced apoptosis, whereas overexpression of heat shock protein (HSP)27, HSP70, HSP90 and T‐cell factor 4 is associated with bortezomib resistance.

[1]  C. Hoogenraad,et al.  ATF3 expression precedes death of spinal motoneurons in amyotrophic lateral sclerosis‐SOD1 transgenic mice and correlates with c‐Jun phosphorylation, CHOP expression, somato‐dendritic ubiquitination and Golgi fragmentation , 2005, The European journal of neuroscience.

[2]  Tsonwin Hai,et al.  Activating transcription factor 3, a stress sensor, activates p53 by blocking its ubiquitination , 2005, The EMBO journal.

[3]  N. Munshi,et al.  Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-β inhibitors , 2005, Oncogene.

[4]  J. Myers,et al.  Gene expression profiling identifies activating transcription factor 3 as a novel contributor to the proapoptotic effect of curcumin. , 2005, Molecular cancer therapeutics.

[5]  T. Yano,et al.  Ovariectomy aggravates hypersensitivity reactions to paclitaxel in rats , 2005, Cancer biology & therapy.

[6]  B. Wouters,et al.  Activating Transcription Factor 4 Is Translationally Regulated by Hypoxic Stress , 2004, Molecular and Cellular Biology.

[7]  T. Kipps,et al.  Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Yang Yang,et al.  Proteasome inhibitor PS‐341 induces growth arrest and apoptosis of non‐small cell lung cancer cells via the JNK/c‐Jun/AP‐1 signaling , 2004, Cancer science.

[9]  C. Wen,et al.  Aberrant expression and function of TCF4 in the proliferation of hepatocellular carcinoma cell line BEL-7402 , 2004, Cell Research.

[10]  M. Romeih,et al.  Alterations of β-catenin and Tcf-4 instead of GSK-3β contribute to activation of Wnt pathway in hepatocellular carcinoma , 2003 .

[11]  C. Tabin,et al.  A Tcf4-positive mesodermal population provides a prepattern for vertebrate limb muscle patterning. , 2003, Developmental cell.

[12]  Hans Clevers,et al.  TCF and Groucho-related genes influence pituitary growth and development. , 2003, Molecular endocrinology.

[13]  D. Chauhan,et al.  Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. , 2003, Cancer research.

[14]  I. Yang,et al.  Regulation of caspase expression and apoptosis by adenomatous polyposis coli. , 2003, Cancer research.

[15]  Bart Barlogie,et al.  A phase 2 study of bortezomib in relapsed, refractory myeloma. , 2003, The New England journal of medicine.

[16]  Christopher J Kane,et al.  The human T-cell factor-4 gene splicing isoforms, Wnt signal pathway, and apoptosis in renal cell carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  I. Weissman,et al.  A role for Wnt signalling in self-renewal of haematopoietic stem cells , 2003, Nature.

[18]  T. Rowlands,et al.  β-Catenin and Tcfs in Mammary Development and Cancer , 2003, Journal of Mammary Gland Biology and Neoplasia.

[19]  R. Kaufman,et al.  All roads lead to ATF4. , 2003, Developmental cell.

[20]  J. Rubin,et al.  Wnt signaling in B-cell neoplasia , 2003, Oncogene.

[21]  K. Anderson,et al.  Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. , 2003, Blood.

[22]  Beverly S Mitchell,et al.  Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  T. Libermann,et al.  Molecular sequelae of proteasome inhibition in human multiple myeloma cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[24]  D. Neuberg,et al.  Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. , 2002, Cancer research.

[25]  S. Soignet,et al.  A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  Meland,et al.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[27]  H. Clevers,et al.  WNT Signaling and Lymphocyte Development , 2002, Cell.

[28]  H. Clevers,et al.  TCF transcription factors, mediators of Wnt-signaling in development and cancer. , 2002, Developmental biology.

[29]  J. Adams.  Development of the proteasome inhibitor PS-341. , 2002, The oncologist.

[30]  K. Anderson,et al.  Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. , 2001, Blood.

[31]  J. Taipale,et al.  The Hedgehog and Wnt signalling pathways in cancer , 2001, Nature.

[32]  P. Elliott,et al.  The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. , 2001, Cancer research.

[33]  K. Lindsten,et al.  Lack of proteasome active site allostery as revealed by subunit-specific inhibitors. , 2001, Molecular cell.

[34]  Marty W. Mayo,et al.  WNT-1 Signaling Inhibits Apoptosis by Activating β-Catenin/T Cell Factor–Mediated Transcription , 2001, The Journal of cell biology.

[35]  C. Li,et al.  Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[36]  S-G Hwang,et al.  Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition , 2000, Leukemia.

[37]  P. Elliott,et al.  Proteasome inhibition measurements: clinical application. , 2000, Clinical chemistry.

[38]  M. Peifer,et al.  Wnt signaling in oncogenesis and embryogenesis--a look outside the nucleus. , 2000, Science.

[39]  C. Sensen,et al.  Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency , 1999, Nature Genetics.

[40]  E. Sausville,et al.  Proteasome inhibitors: a novel class of potent and effective antitumor agents. , 1999, Cancer research.

[41]  T. Reinheckel,et al.  Poly-ADP ribose polymerase activates nuclear proteasome to degrade oxidatively damaged histones. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[42]  A. Sparks,et al.  Identification of c-MYC as a target of the APC pathway. , 1998, Science.

[43]  H Clevers,et al.  Two Members of the Tcf Family Implicated in Wnt/β-Catenin Signaling during Embryogenesis in the Mouse , 1998, Molecular and Cellular Biology.

[44]  F. Dilworth,et al.  cDNA Cloning of Human Retinoic Acid-metabolizing Enzyme (hP450RAI) Identifies a Novel Family of Cytochromes P450 (CYP26)* , 1997, The Journal of Biological Chemistry.

[45]  K. Kinzler,et al.  Constitutive Transcriptional Activation by a β-Catenin-Tcf Complex in APC−/− Colon Carcinoma , 1997, Science.

[46]  S. Korsmeyer,et al.  Immunoglobulin gene rearrangements and expression in diffuse histiocytic lymphomas reveal cellular lineage, molecular defects, and sites of chromosomal translocation. , 1986, Blood.

[47]  S. Korsmeyer,et al.  Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around Jh on chromosome 14 and near a transcriptional unit on 18 , 1985, Cell.

[48]  R. Kaufman,et al.  A trip to the ER: coping with stress. , 2004, Trends in cell biology.

[49]  E. Vokes,et al.  Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  Frank Petersen,et al.  Small-molecule antagonists of the oncogenic Tcf/β-catenin protein complex , 2004 .

[51]  Frank Petersen,et al.  Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. , 2004, Cancer cell.

[52]  M. Romeih,et al.  Alterations of beta-catenin and Tcf-4 instead of GSK-3beta contribute to activation of Wnt pathway in hepatocellular carcinoma. , 2003, Chinese medical journal.

[53]  H Clevers,et al.  Restricted high level expression of Tcf-4 protein in intestinal and mammary gland epithelium. , 1999, The American journal of pathology.

[54]  F. McCormick,et al.  Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. , 1999, Nature.

[55]  K Tanaka,et al.  Structure and functions of the 20S and 26S proteasomes. , 1996, Annual review of biochemistry.